Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions

Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2003, Pages 883-908

  Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ACOLBIFENE; ANTIESTROGEN; CENTCHROMAN; CHROMAN DERIVATIVE; CLOMIFENE CITRATE; CONTRACEPTIVE AGENT; DIETHYLSTILBESTROL; ENCLOMIFENE; ESTRADIOL; ESTROGEN; ETHAMOXYTRIPHETOL; FULVESTRANT; GENISTEIN; GESTAGEN; GW 7604; INDENE DERIVATIVE; IODOXIFENE; LY 133314; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NAFOXIDINE; NITROMIFENE; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; TRIOXIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZUCLOMIFENE;

ALZHEIMER DISEASE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTRACEPTION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OSTEOPOROSIS; OVULATION INDUCTION; PHOTOPHOBIA; POSTMENOPAUSE; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; UTERUS CANCER;

ANIMALS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; HUMANS; MODELS, MOLECULAR; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037435046     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020449y     Document Type: Review

References (357)

1. Drill, V. A. History of the first oral contraceptive. J. Toxicol. Environ. Health 1977, 3, 133-138.
2. Kronenberg, F. Hot Flashes. In Treatment of the Postmenopausal Woman: Basic and Clinical Aspects; Lobo, R. A., Ed.; Raven Press: New York, 1994; pp 97-117.
3. Belchetz, P. E. Hormonal treatment of postmenopausal women. N. Engl. J. Med. 1994, 330, 1062-1071.
4. Shipman, A. J.; Guy, G. W.; Smith, I.; Ostlere, S.; Greer, W.; Smith, R. Vertebral bone mineral density, content and area in 8789 normal women aged 33-73 years who have never had hormone replacement therapy. Osteoporosis Int. 1999, 9, 420-426.
5. Aitken, J. M.; Hart, D. M.; Anderson, J. B.; Lindsay, R.; Smith, D. A.; Speirs, C. F. Osteoporosis after oophorectomy for nonmalignant disease in premenopausal women. Br. Med. J. 1973, 2, 325-328.
6. The-Writing-Group-for-the-PEPI effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA, J. Am. Med. Assoc. 1996, 276, 1389-1396.
7. C4 consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 1993, 94, 646-650.
8. Barrett-Connor, E.; Grady, D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Public Health 1998, 19, 55-72.
9. Paganini-Hill, A.; Henderson, V. W. Estrogen replacement therapy and risk of Alzheimer disease. Arch. Intern. Med. 1996, 156, 2213-2217.
10. Tang, M. X.; Jacobs, D.; Stern, Y.; Marder, K.; Schofield, P.; Gurland, B.; Andrews, H.; Mayeux, R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease [see comments]. Lancet 1996, 348, 429-432.
11. Mulnard, R. A.; Cotman, C. W.; Kawas, C.; van Dyck, C. H.; Sano, M.; Doody, R.; Koss, E.; Pfeiffer, E.; Jin, S.; Gamst, A.; Grundman, M.; Thomas, R.; Thal, L. J. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA, J. Am. Med. Assoc. 2000, 283, 1007-1015.
12. Hulley, S.; Grady, D.; Bush, T.; Furberg, C.; Herrington, D.; Riggs, B.; Vittinghoff, E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA, J. Am. Med. Assoc. 1998, 280, 605-613.
13. Grady, D.; Applegate, W.; Bush, T.; Furberg, C.; Riggs, B.; Hulley, S. B. Heart and Estrogen/Progestin Replacement Study (HERS): Design, Methods, and Baseline Characteristics. Controlled Clin. Trials 1998, 19, 314-335.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women principal results from the women's health initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 2002, 288, 321-333.
15. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2, 104-107.
16. Boyd, S. On oophorectomy in cancer of the breast. Br. Med. J. 1900, 2, 1161-1167.
17. Jensen, E. V.; Jacobson, H. I. Fate of steroidal estrogens in target tissues. In Biological Activities of Steroids in Relation to Cancer; Pincus, G., Vollmer, E. P., Eds.; Academic Press: New York, 1960; pp 161-174.
18. Jensen, E. V.; Jacobson, H. I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 1962, 18, 387-414.
19. Toft, D.; Gorski, J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc. Natl. Acad. Sci. U.S.A. 1966, 55, 1574-1581.
20. Toft, D.; Shyamala, G.; Gorski, J. A receptor molecule for estrogens: studies using a cell-free system. Proc. Natl. Acad. Sci. U.S.A. 1967, 57, 1740-1743.
21. Gorski, J.; Toft, D.; Shyamala, G.; Smith, D.; Notides, A. Hormone receptors: studies on the interaction of estrogen with the uterus. Recent Prog. Horm. Res. 1968, 24, 45-80.
22. Jensen, E. V.; Suzuki, T.; Kawashima, T.; Stumpf, W. E.; Jungblut, P. W.; DeSombre, E. R. A two-step mechanism for the interaction of estradiol with rat uterus. Proc. Natl. Acad. Sci. U.S.A. 1968, 59, 632-638.
23. Jensen, E. V.; Greene, G. L.; Closs, L. E.; DeSombre, E. R.; Nadji, M. Receptors reconsidered: a 20-year perspective. Recent Prog. Horm. Res. 1982, 38, 1-40.
24. Gorski, J.; Welshons, W.; Sakai, D. Remodeling the estrogen receptor model. Mol. Cell. Endocrinol. 1984, 36, 11-15.
25. Jensen, E. V.; Block, G. E.; Smith, S.; Kyser, K.; DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr. 1971, 34, 55-70.
26. McGuire, W. L.; Carbone, P. P.; Vollmer, E. P. Estrogen Receptors in Human Breast Cancer; Raven Press: New York, 1975.
27. Lerner, L. J.; Jordan, V. C. The development of antiestrogens for the treatment of breast cancer. Cancer Res. 1990, 50, 4177-4189.
28. Jordan, V. C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat. 1988, 11, 197-209.
29. Gottardis, M. M.; Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987, 47, 4020-4024.
30. Powles, T. J.; Hardy, J. R.; Ashley, S. E.; Farrington, G. M.; Cosgrove, D.; Davey, J. B.; Dowsett, M.; McKinna, J. A.; Nash, A. G.; Sinnett, H. D.; et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 1989, 60, 126-131.
31. Jordan, V. C.; Phelps, E.; Lindgren, J. U. Effects of anti -estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 1987, 10, 31-35.
32. Turner, R. T.; Wakley, G. K.; Hannon, K. S.; Bell, N. H. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J. Bone Miner. Res. 1987, 2, 449-456.
33. Turner, R. T.; Wakley, G. K.; Hannon, K. S.; Bell, N. H. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 1988, 122, 1146-1150.
34. Turken, S.; Siris, E.; Seldin, D.; Flaster, E.; Hyman, G.; Lindsay, R. Effects of tamoxifen on spinal bone density in women with breast cancer. J. Natl. Cancer Inst. 1989, 81, 1086-1088.
35. Love, R. R.; Mazess, R. B.; Barden, H. S.; Epstein, S.; Newcomb, P. A.; Jordan, V. C.; Carbone, P. P.; DeMets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer [see comments]. N. Engl. J. Med. 1992, 326, 852-856.
36. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Redmond, C. K.; Kavanah, M.; Cronin, W. M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 1998, 90, 1371-1388.
37. Jordan, V. C.; Morrow, M. Raloxifene as a multifunctional medicine? Br. Med. J. 1999, 319, 331-332.
38. Jordan, V. C.; Gapstur, S.; Morrow, M. Selective estrogen receptor modulation to reduce breast cancer risk, osteoporosis and coronary heart disease. J. Natl. Cancer Inst. 2001, 93, 1449-1457.
39. Jordan, V. C. Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. J. Natl. Cancer Inst. 2001, 93, 2-4.
40. Walter, P.; Green, S.; Greene, G.; Krust, A.; Bornert, J. M.; Jeltsch, J. M.; Staub, A.; Jensen, E.; Scrace, G.; Waterfield, M.; et al. Cloning of the human estrogen receptor cDNA. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7889-7893.
41. Green, S.; Walter, P.; Kumar, V.; Krust, A.; Bornert, J. M.; Argos, P.; Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320, 134-139.
42. Greene, G. L.; Gilna, P.; Waterfield, M.; Baker, A.; Hort, Y.; Shine, J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231, 1150-1154.
43. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5925-5930.
44. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392, 49-53.
45. Tremblay, G. B.; Tremblay, A.; Copeland, N. G.; Gilbert, D. J.; Jenkins, N. A.; Labrie, F.; Giguere, V. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol. 1997, 11, 353-365.
46. Couse, J. F.; Curtis, S. W.; Washburn, T. F.; Lindzey, J.; Golding, T. S.; Lubahn, D. B.; Smithies, O.; Korach, K. S. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol. Endocrinol. 1995, 9, 1441-1454.
47. Korach, K. S.; Couse, J. F.; Curtis, S. W.; Washburn, T. F.; Lindzey, J.; Kimbro, K. S.; Eddy, E. M.; Migliaccio, S.; Snedeker, S. M.; Lubahn, D. B.; Schomberg, D. W.; Smith, E. P. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog. Horm. Res. 1996, 51, 159-186.
48. Couse, J. F.; Korach, K. S. Exploring the role of sex steroids through studies of receptor deficient mice [see comments]. J. Mol. Med. 1998, 76, 497-511.
49. Kumar, V.; Green, S.; Stack, G.; Berry, M.; Jin, J. R.; Chambon, P. Functional domains of the human estrogen receptor. Cell 1987, 51, 941-951.
50. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustafsson, J. A. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 1997, 82, 4258-4265.
51. Montano, M. M.; Muller, V.; Trobaugh, A.; Katzenellenbogen, B. S. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol. 1995, 9, 814-825.
52. Peters, G. A.; Khan, S. A. Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140. Mol. Endocrinol. 1999, 13, 286-296.
53. Ponglikitmongkol, M.; Green, S.; Chambon, P. Genomic organization of the human oestrogen receptor gene. EMBO J. 1988, 7, 3385-3388.
54. Ogawa, S.; Inoue, S.; Watanabe, T.; Hiroi, H.; Orimo, A.; Hosoi, T.; Ouchi, Y.; Muramatsu, M. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem. Biophys. Res. Commun. 1998, 243, 122-126.
55. Ogawa, S.; Inoue, S.; Watanabe, T.; Orimo, A.; Hosoi, T.; Ouchi, Y.; Muramatsu, M. Molecular cloning and characterization of human estrogen receptor beta cx: a potential inhibitor of estrogen action in human. Nucleic Acids Res. 1998, 26, 3505-3512.
56. Berry, M.; Metzger, D.; Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990, 9, 2811-2818.
57. Metzger, D.; Ali, S.; Bornert, J. M.; Chambon, P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem. 1995, 270, 9535-9542.
58. Weigel, N. L.; Zhang, Y. Ligand-independent activation of steroid hormone receptors [see comments]. J. Mol. Med. 1998, 76, 469-479.
59. Aronica, S. M.; Katzenellenbogen, B. S. Stimulation ofestrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 1993, 7, 743-752.
60. Bunone, G.; Briand, P. A.; Miksicek, R. J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
61. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
62. Tremblay, G. B.; Tremblay, A.; Labrie, F.; Giguere, V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. Mol. Cell. Biol. 1999, 19, 1919-1927.
63. Tremblay, A.; Tremblay, G. B.; Labrie, F.; Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell 1999, 3, 513-519.
64. Lees, J. A.; Fawell, S. E.; Parker, M. G. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res. 1989, 17, 5477-5488.
65. Danielian, P. S.; White, R.; Lees, J. A.; Parker, M. G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors [published erratum appears in EMBO J. 1992 11 (6), 2366]. EMBO J. 1992, 11, 1025-1033.
66. Wrenn, C. K.; Katzenellenbogen, B. S. Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J. Biol. Chem. 1993, 268, 24089-24098.
67. Tzukerman, M. T.; Esty, A.; Santiso-Mere, D.; Danielian, P.; Parker, M. G.; Stein, R. B.; Pike, J. W.; McDonnell, D. P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 1994, 8, 21-30.
68. Beato, M.; Sanchez-Pacheco, A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr. Rev. 1996, 17, 587-609.
69. Cavailles, V.; Dauvois, S.; Danielian, P. S.; Parker, M. G. Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10009-10013.
70. L'Horset, F.; Dauvois, S.; Heery, D. M.; Cavailles, V.; Parker, M. G. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell. Biol. 1996, 16, 6029-6036.
71. vom Baur, E.; Zechel, C.; Heery, D.; Heine, M. J.; Garnier, J. M.; Vivat, V.; Le Douarin, B.; Gronemeyer, H.; Chambon, P.; Losson, R. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 1996, 15, 110-124.
72. Kraus, W. L.; McInerney, E. M.; Katzenellenbogen, B. S. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 12314-12318.
73. Pace, P.; Taylor, J.; Suntharalingam, S.; Coombes, R. C.; Ali, S. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J. Biol. Chem. 1997, 272, 25832-25838.
74. Paech, K.; Webb, P.; Kuiper, G. G.; Nilsson, S.; Gustafsson, J.; Kushner, P. J.; Scanlan, T. S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites [see comments]. Science 1997, 277, 1508-1510.
75. Webb, P.; Lopez, G. N.; Uht, R. M.; Kushner, P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 1995, 9, 443-456.
76. Webb, P.; Nguyen, P.; Valentine, C.; Lopez, G. N.; Kwok, G. R.; McInerney, E.; Katzenellenbogen, B. S.; Enmark, E.; Gustafsson, J. A.; Nilsson, S.; Kushner, P. J. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol. Endocrinol. 1999, 13, 1672-1685.
77. Zou, A.; Marschke, K. B.; Arnold, K. E.; Berger, E. M.; Fitzgerald, P.; Mais, D. E.; Allegretto, E. A. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol. 1999, 13, 418-430.
78. Saville, B.; Wormke, M.; Wang, F.; Nguyen, T.; Enmark, E.; Kuiper, G.; Gustafsson, J. A.; Safe, S. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 2000, 275, 5379-5387.
79. Pettersson, K.; Grandien, K.; Kuiper, G. G.; Gustafsson, J. A. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol. Endocrinol. 1997, 11, 1486-1496.
80. Cowley, S. M.; Hoare, S.; Mosselman, S.; Parker, M. G. Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 1997, 272, 19858-19862.
81. Hall, J. M.; McDonnell, D. P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140, 5566-5578.
82. Goss, P.; Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 2001, 19, 881-894.
83. Nilsson, S.; Makela, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G.; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J. A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81, 1535-1565.
84. Horwitz, K. B.; Jackson, T. A.; Bain, D. L.; Richer, J. K.; Takimoto, G. S.; Tung, L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 1996, 10, 1167-1177.
85. McKenna, N. J.; Lanz, R. B.; O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20, 321-344.
86. Brzozowski, A. M.; Pike, A. C.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-758.
87. Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5998-6003.
88. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998, 95, 927-937.
89. Feng, W.; Ribeiro, R. C.; Wagner, R. L.; Nguyen, H.; Apriletti, J. W.; Fletterick, R. J.; Baxter, J. D.; Kushner, P. J.; West, B. L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998, 280, 1747-1749.
90. Moras, D.; Gronemeyer, H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 1998, 10, 384-391.
91. Gangloff, M.; Ruff, M.; Eiler, S.; Duclaud, S.; Wurtz, J. M.; Moras, D. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. J. Biol. Chem. 2001, 276, 15059-15065.
92. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-4618.
93. Sadovsky, Y.; Webb, P.; Lopez, G.; Baxter, J. D.; Fitzpatrick, P. M.; Gizang-Ginsberg, E.; Cavailles, V.; Parker, M. G.; Kushner, P. J. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol. Cell. Biol. 1995, 15, 1554-1563.
94. Brou, C.; Wu, J.; Ali, S.; Scheer, E.; Lang, C.; Davidson, I.; Chambon, P.; Tora, L. Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL- VP16 and the two nonacidic activation functions of the estrogen receptor. Nucleic Acids Res. 1993, 21, 5-12.
95. Ing, N. H.; Beekman, J. M.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J. Biol. Chem. 1992, 267, 17617-17623.
96. Jacq, X.; Brou, C.; Lutz, Y.; Davidson, I.; Chambon, P.; Tora, L. Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell 1994, 79, 107-117.
97. Spencer, T. E.; Jenster, G.; Burcin, M. M.; Allis, C. D.; Zhou, J.; Mizzen, C. A.; McKenna, N. J.; Onate, S. A.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997, 389, 194-198.
98. Halachmi, S.; Marden, E.; Martin, G.; MacKay, H.; Abbondanza, C.; Brown, M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994, 264, 1455-1458.
99. Cavailles, V.; Dauvois, S.; L'Horset, F.; Lopez, G.; Hoare, S.; Kushner, P. J.; Parker, M. G. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 1995, 14, 3741-3751.
100. Onate, S. A.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270, 1354-1357.
101. Onate, S. A.; Boonyaratanakornkit, V.; Spencer, T. E.; Tsai, S. Y.; Tsai, M. J.; Edwards, D. P.; O'Malley, B. W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 1998, 273, 12101-12108.
102. Zwijsen, R. M.; Buckle, R. S.; Hijmans, E. M.; Loomans, C. J.; Bernards, R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 1998, 12, 3488-3498.
103. Lanz, R. B.; McKenna, N. J.; Onate, S. A.; Albrecht, U.; Wong, J.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999, 97, 17-27.
104. Hanstein, B.; Eckner, R.; DiRenzo, J.; Halachmi, S.; Liu, H.; Searcy, B.; Kurokawa, R.; Brown, M. p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11540-11545.
105. Kamei, Y.; Xu, L.; Heinzel, T.; Torchia, J.; Kurokawa, R.; Gloss, B.; Lin, S. C.; Heyman, R. A.; Rose, D. W.; Glass, C. K.; Rosenfeld, M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85, 403-414.
106. Chakravarti, D.; LaMorte, V. J.; Nelson, M. C.; Nakajima, T.; Schulman, I. G.; Juguilon, H.; Montminy, M.; Evans, R. M. Role of CBP/P300 in nuclear receptor signalling [see comments]. Nature 1996, 383, 99-103.
107. Anzick, S. L.; Kononen, J.; Walker, R. L.; Azorsa, D. O.; Tanner, M. M.; Guan, X.; Sauter, G.; Kallioniemi, O.; Trent, J. M.; Meltzer, P. S. A1B1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277, 965-968.
108. Bautista, S.; Valles, H.; Walker, R. L.; Anzick, S.; Zeillinger, R.; Meltzer, P.; Theillet, C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 1998, 4, 2925-2929.
109. Li, H.; Chen, D. The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation. J. Biol. Chem. 1998, 273, 5948-5954.
110. Xu, J.; Liao, L.; Yoshida-Komiya, H.; Deng, C.; O'Malley, B. W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1, ACTR/TRAM-1) is required for normal growth, puberty, female reprodcutive function, and mammary gland development. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6379-6384.
111. Tikkanen, M. K.; Carter, D. J.; Harris, A. M.; Le, H. M.; Azorsa, D. O.; Meltzer, P. S.; Murdoch, F. E. Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12536-12540.
112. List, H.-J.; Lauritsen, K. J.; Reiter, R.; Powers, C.; Wellstein, A.; Riegel, A. T. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J. Biol. Chem. 2001, 276, 23763-23768.
113. Font de Mora, J.; Brown, M. AIB1 is a conduit for kinasemediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 2000, 20, 5041-5047.
114. Reiter, R.; Wellstein, A.; Reigel, A. T. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J. Biol. Chem. 2001, 276, 39736-39741.
115. Gee, A. C.; Carlson, K. E.; Martini, P. G.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol. Endocrinol. 1999, 13, 1912-1923.
116. Klinge, C. M. Estrogen receptor binding to estrogen response elements slows ligand dissociation and synergistically activates reporter gene expression. Mol. Cell. Endocrinol. 1999, 150, 99-111.
117. Hall, J. M.; McDonnell, D. P.; Korach, K. S. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by differenct estrogen response elements. Mol. Endocrinol. 2002, 16, 469-486.
118. Klinge, C. M. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF). J. Steroid Biochem. Mol. Biol. 1999, 71, 1-19.
119. McDonnell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
120. Wijayaratne, A. L.; Nagel, S. C.; Paige, L. A.; Christensen, D. J.; Norris, J. D.; Fowlkes, D. M.; McDonnell, D. P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999, 140, 5828-5840.
121. MacGregor-Shafer, J. I.; Liu, H.; Bentrem, D.; Zapf, J.; Jordan, V. C. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex by substituting glycine for aspartate at amino acid 351. Cancer Res. 2000, 60, 5097-5105.
122. Norris, J. D.; Paige, L. A.; Christensen, D. J.; Chang, C. Y.; Huacani, M. R.; Fan, D.; Hamilton, P. T.; Fowlkes, D. M.; McDonnell, D. P. Peptide antagonists of the human estrogen receptor. Science 1999, 285, 744-746.
123. Paige, L. A.; Christensen, D. J.; Gron, H.; Norris, J. D.; Gottlin, E. B.; Padilla, K. M.; Chang, C. Y.; Ballas, L. M.; Hamilton, P. T.; McDonnell, D. P.; Fowlkes, D. M. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3999-4004.
124. Levenson, A. S.; MacGregor Schafer, J. I.; Bentrem, D. J.; Pease, K. M.; Jordan, V. C. Control of the estrogen-like actions of tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J. Steroid Biochem. Mol. Biol. 2001, 76, 61-70.
125. Stenoien, D. L.; Mancini, M. G.; Patel, K.; Allegretto, E. A.; Smith, C. L.; Mancini, M. A. Subnuclear trafficking of estrogen receptor-alpha and steroid receptor coactivator-1. Mol. Endocrinol. 2000, 14, 518-534.
126. Weatherman, R. V.; Chang, C.-Y.; Clegg, N. J.; Carroll, D. C.; Day, R. N.; Baxter, J. D.; McDonnell, D. P.; Scanlan, T. S.; Schaufele, F. Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer. Mol. Endocrinol. 2002, 16, 487-496.
127. Giguere, V.; Yang, N.; Segui, P.; Evans, R. M. Identification of a new class of steroid hormone receptors. Nature 1988, 331, 91-94.
128. Shi, H.; Shigeta, H.; Yang, N.; Fu, K.; O'Brian, G.; Teng, C. T. Human estrogen receptor like 1 (ESRL1) gene: genomic organization, chromosomal localization, and promoter characterization. Genomics 1997, 44, 52-60.
129. Johnston, S. D.; Liu, X.; Zuo, F.; Eisenbraun, T. L.; Wiley, S. R.; Kraus, R. J.; Mertz, J. E. Estrogen-related receptor alpha 1 functionally binds as a momomer to extended half-site sequences including ones contained within estrogen-response elements. Mol. Endocrinol. 1997, 11, 342-352.
130. Chen, F.; Zhang, Q.; McDonald, T.; Davidoff, M. J.; Bailey, W.; Bai, C.; Liu, Q.; Caskey, C. T. Identification of two hERR2-related novel nuclear receptors utilizing bioinformatics and inverse PCR. Gene 1999, 28, 101-109.
131. Eudy, J. D.; Yao, S.; Weston, M. D.; Ma-Edmonds, M.; Talmadge, C. B.; Cheng, J. J.; Kimberling, W. J.; Sumegi, J. Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41. Genomics 1998, 14, 382-384.
132. Heard, D. J.; Norby, P. L.; Holloway, J.; Vissing, H. Human ERRgamma, a third member of the estrogen receptor-related (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol. Endocrinol. 2000, 14, 382-392.
133. Kraus, R. J.; Ariazi, E. A.; Farrell, M. L.; Mertz, J. E. Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. J. Biol. Chem., in press.
134. Vanacker, J. M.; Pettersson, K.; Gustafsson, J. A.; Laudet, V. Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J. 1999, 18, 4270-4279.
135. Hong, H.; Yang, L.; Stallcup, M. R. Hormone-independent transcriptional activiation and coactivator binding by novel orphan nuclear receptor ERR3. J. Biol. Chem. 1999, 274, 22618-22626.
136. Coward, P.; Lee, D.; Hull, M. V.; Lehmann, J. M. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 8880-8884.
137. Vanacker, J. M.; Bonnelye, E.; Chopin-Delannoy, S.; Delmarre, C.; Cavailles, V.; Laudet, V. Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). Mol. Endocrinol. 1999, 13, 764-773.
138. Bonnelye, E.; Vanacker, J. M.; Spruyt, N.; Alric, S.; Fournier, B.; Desbiens, X.; Laudet, V. Expression of the estrogen-related receptor 1 (ERR-1) orphan receptor during mouse development. Mech. Dev. 1997, 65, 71-85.
139. Sladek, R.; Bader, J. A.; Giguere, V. The orphan nuclear receptor estrogen-related receptor alpha is a trascriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene. Mol. Cell. Biol. 1997, 17, 5400-5409.
140. Xie, W.; Hong, H.; Yang, N. N.; Lin, R. J.; Simon, C. M.; Stallcup, M. R.; Evans, R. M. Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. Mol. Endocrinol. 1999, 13, 2151-2162.
141. Trembley, G. B.; Kunath, T.; Bergeron, D.; Lapointe, L.; Champigny, C.; Bader, J. A.; Rossant, J.; Giguere, V. Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes Dev. 2001, 15, 833-838.
142. Greschik, H.; Wurtz, J. M.; Sanglier, S.; Bourguet, W.; van Dorsselaer, A.; Moras, D.; Renaud, J. P. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol. Cell 2002, 9, 303-313.
143. Chen, S.; Zhou, D.; Yang, C.; Sherman, M. Molecular basis for the constitutive activity of estrogen related receptor a-1 (ERRa-1). J. Biol. Chem. 2001, 276, 28465-28470.
144. Trembley, G. B.; Bergeron, D.; Giguere, V. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma. Endocrinology 2001, 142, 4572-4575.
145. Lu, D.; Kiriyama, Y.; Lee, K. Y.; Giguere, V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res. 2001, 61, 6755-6761.
146. Yang, N.; Shigeta, H.; Shi, H.; Teng, C. T. Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter. J. Biol. Chem. 1996, 271, 5795-5804.
147. Bonnelye, E.; Vanacker, J. M.; Dittmar, T.; Begue, A.; Desbiens, X.; Denhardt, D. T.; Aubin, J. E.; Laudet, V.; Fournier, B. The ERR-1 orphan receptor is a transcriptional activator expresssed during bone development. Mol. Endocrinol. 1997, 11, 905-916.
148. Vanacker, J. M.; Delmarre, C.; Guo, X.; Laudet, V. Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related alpha. Cell Growth Differ. 1998, 9, 1007-1014.
149. Yang, C.; Zhou, D.; Chen, S. Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Res. 1998, 58, 5695-5700.
150. Yang, C.; Chen, S. Two organohlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related alpha-1 orphan receptor. Cancer Res. 1999, 59, 4519-4524.
151. Zhang, Z.; Teng, C. T. Estrogen receptor-related receptor alpha 1 interacts with coactivator and constitutively activates the estrgoen response elements of the human lactoferrin gene. J. Biol. Chem. 2000, 275, 20837-20846.
152. Zhang, Z.; Teng, C. T. Estrogen receptor alpha and estrogen receptor-related receptor alpha 1 compete for binding and coactivator. Mol. Cell. Endocrinol. 2001, 172, 223-233.
153. Jordan, V. C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev. 1984, 36, 245-276.
154. Jordan, V. C.; Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 1990, 11, 578-610.
155. MacGregor Schafer, J. I.; Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998, 50, 151-196.
156. Jordan, V. C.; Morrow, M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev. 1999, 20, 253-278.
157. Lerner, L. J.; Holthaus, J. F.; Thompson, C. R. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl- 2-p-methoxyphenylethanol. Endocrinology 1958, 63, 295-318.
158. Barnes, J. E.; Meyer, R. K. Effects of ethamoxytriphetol, MRL37 and clomiphene or reproduction in rats. Fertil. Steril. 1962, 13, 472-480.
159. Chang, M. C. Degeneration of ova in the rat and rabbit following oral administration of 1-(p-diethylaminoethoxyphenyl)-1-phenyl-2-p-anisylethanol. Endocrinology 1959, 65, 339-342.
160. Segal, J. S.; Nelson, W. O. An orally active compound with antifertility effects in rats. Proc. Soc. Exp. Biol. Med. 1958, 98, 431-436.
161. Emmens, C. W. Postcoital contraception. Br. Med. Bull. 1970, 26, 45-51.
162. Holtkamp, D. E.; Greslin, S. C.; Root, C. A.; Lerner, L. J. Gonadotropin inhibiting and antifecundity effects of chloramiphene. Proc. Soc. Exp. Biol. Med. 1960, 105, 197-201.
163. Segal, J. S.; Nelson, W. O. Antifertility action of chloramiphene. Anat. Rec. 1961, 139, 273.
164. Duncan, G. W.; Lyster, S. C.; Clark, J. J.; Lednicer, D. Antifertility activities of two diphenyl-dihydronaphthalene derivatives. Proc. Soc. Exp. Biol. Med. 1963, 112, 439-442.
165. Greenwald, G. S. Effects of a dihydronaphthalene derivation (U 11,100A) on pregnancy in the rat. Fertil. Steril. 1965, 16, 185-194.
166. Callantine, M. R.; Humphrey, R. R.; Lee, S. L.; Windsor, B. L.; Schottin, N. H.; O'Brien, O. P. Action of an estrogen antagonist on reproductive mechanisms in the rat. Endocrinology 1966, 79, 153-169.
167. Harper, M. J.; Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 1967, 13, 101-119.
168. Harper, M. J.; Walpole, A. L. Mode of action of I.C.I. 46,474 in preventing implantation in rats. J. Endocrinol. 1967, 37, 83-92.
169. Greenblatt, R. B.; Barfield, W. E.; Jungck, E. C.; Ray, A. W. Induction of ovulation with MRL-41 - Preliminary Report. JAMA, J. Am. Med. Assoc. 1961, 178, 101-104.
170. Huppert, L. C. Induction of ovulation with clomiphene citrate. Fertil. Steril. 1979, 31, 1-8.
171. Boostanfar, R.; Jain, J. K.; Mishell, D. R., Jr.; Paulson, R. J. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril. 2001, 75, 1024-1026.
172. Klopper, A.; Hall, M. New synthetic agent for the induction of ovulation. Preliminary trial in women. Br. Med. J. 1971, 1, 152-154.
173. Williamson, J. G.; Ellis, J. D. The induction of ovulation by tamoxifen. J. Obstet. Gynaecol. Br. Commonw. 1973, 80, 844-847.
174. Harper, M. J.; Walpole, A. L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966, 212, 87.
175. Bedford, G.; Richardson, D. N. Preparation and identification of cis and trans isomers of a substituted triphenylethylene. Nature 1966, 212, 733-734.
176. Kilbourn, B.; Mais, R. H. B.; Owston, P. G. Identification of isomers ofa substituted triphenylethylene: the crystal structure of 1-p-(2-dimethylaminoethoxyphenyl)1,2 cis diphenyl but1-ene hydrobromide. Chem. Commun. 1968, 1, 291.
177. Kilbourn, B.; Owston, P. G. Crystal structure of the hydrobromide of 1-p-(2 dimethylamino ethoxyphenyl)-1,2 cis diphenyl but-1-ene, a compound with oestrogenic activity. J. Chem. Soc. B 1970, 1-5.
178. Palopoli, F. P.; Feil, V. J.; Allen, R. F.; Holtkamp, D. E.; Richardson, A., Jr. Substituted aminoalkoxyl-triarylhaloethylenes. J. Med. Chem. 1967, 10, 84-86.
179. Jordan, V. C.; Haldemann, B.; Allen, K. E. Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology 1981, 108, 1353-1361.
180. Clark, J. H.; Guthrie, S. C. Agonistic and antagonistic effects of clomiphene citrate and its isomer. Biol. Reprod. 1981, 25, 667-672.
181. Camerman, N.; Chan, L. Y.; Camerman, A. Crystal and molecular structure of nafoxidine and stereochemical features of anticancer antiestrogens. J. Med. Chem. 1980, 23, 941-945.
182. Kamboj, V. P.; Setty, B. S.; Chandra, H.; Roy, S. K.; Kar, A. B. Biological profile of Centchroman - a new post-coital contraceptive. Indian J. Exp. Biol. 1977, 15, 1144-1150.
183. Ray, S.; Grover, P. K.; Kamboj, V. P.; Setty, B. S.; Kar, A. B.; Anand, N. Antifertility agents. 12. Structure-activity relationship of 3,4-diphenylchromenes and -chromans. J. Med. Chem. 1976, 19, 276-279.
184. Salman, M.; Ray, S.; Agarwal, A. K.; Durani, S.; Setty, B. S.; Kamboj, V. P.; Anand, N. Antifertility agents. 38. Effect of the side chain and its position on the activity of 3,4-diarylchromans. J. Med. Chem. 1983, 26, 592-595.
185. Salman, M.; Ray, S.; Anand, N.; Agarwal, A. K.; Singh, M. M.; Setty, B. S.; Kamboj, V. P. Studies in antifertility agents. 50. Stereoselective binding of D- and L-centchromans to estrogen receptors and their antifertility activity. J. Med. Chem. 1986, 29, 1801-1803.
186. Ray, S.; Tandon, A.; Dwivedy, I.; Wilson, S. R.; O'Neil, J. P.; Katzenellenbogen, J. A. An X-ray crystallographic study of the nonsteroidal contraceptive agent centchroman. J. Med. Chem. 1994, 37, 696-700.
187. Iyer, R. N.; Gopalchari, R. Studies in potential antifertility agents: Part III. Synthesis of basic ethers from phenolic 2,3-diphenylacrylophenone and related compounds. Indian J. Pharmacol. 1969, 31, 49-54.
188. Iyer, R. N.; Gopalchari, R.; Kamboj, V. P.; Kar, A. B. Antiimplantation effect of 2,3-diphenylacrylophenones. Indian J. Exp. Biol. 1967, 5, 169-170.
189. Gopalchari, R.; Iyer, R. N.; Kamboj, V. P.; Kar, A. B. Antifertility agents-Part V: 3-alkyl-2,3-diphenylpropiophenones. Contraception 1970, 2, 199-205.
190. Jones, C. D.; Suarez, T.; Massey, E. H.; Black, L. J.; Tinsley, F. C. Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl] [4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt. J. Med. Chem. 1979, 22, 962-966.
191. Sharma, A. P.; Saeed, A.; Durani, S.; Kapil, R. S. Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem. 1990, 33, 3216-3222.
192. Black, L. J.; Goode, R. L. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci. 1980, 26, 1453-1458.
193. Lednicer, D.; Lyster, S. C.; Aspergren, B. D.; Duncan, G. W. Mammalian antifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-aryl-2-phenyl-3,4-dihydronaphthalenes, and their derivatives. J. Med. Chem. 1966, 9, 172-176.
194. Lednicer, D.; Babcock, J. C.; Marlatt, P. E.; Lyster, S. C.; Duncan, G. W. Mammalian antifertility agents. I. Derivatives of 2,3-diphenylindenes. J. Med. Chem. 1965, 8, 52-57.
195. Durani, N.; Jain, R.; Saeed, A.; Dikshit, D. K.; Durani, S.; Kapil, R. S. Structure - activity relationship of antiestrogens: a study using triarylbutenone, benzofuran, and triarylfuran analogues as models for triarylethylenes and triarylpropenones. J. Med. Chem. 1989, 32, 1700-1707.
196. Saeed, A.; Sharma, A. P.; Durani, N.; Jain, R.; Durani, S.; Kapil, R. S. Structure - activity relationship of antiestrogens. Studies on 2,3-diaryl-1-benzopyrans. J. Med. Chem. 1990, 33, 3210-3216.
197. Sharma, A. P.; Saeed, A.; Durani, S.; Kapil, R. S. Structure - activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem. 1990, 33, 3222-3229.
198. Cole, M. P.; Jones, C. T.; Todd, I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer 1971, 25, 270-275.
199. Ward, H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J. 1973, 1, 13-14.
200. Jordan, V. C.; Gosden, B. Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol. Cell. Endocrinol. 1982, 27, 291-306.
201. Rose, D. P.; Fischer, A. H.; Jordan, V. C. Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas. Eur. J. Cancer Clin. Oncol. 1981, 17, 893-898.
202. Witte, R. S.; Pruitt, B.; Tormey, D. C.; Moss, S.; Rose, D. P.; Falkson, G.; Carbone, P. P.; Ramirez, G.; Falkson, H.; Pretorius, F. J. A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer 1986, 57, 34-39.
203. Lee, R. W.; Buzdar, A. U.; Blumenschein, G. R.; Hortobagyi, G. N. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 1986, 57, 40-43.
204. Legha, S. S.; Carter, S. K. Antiestrogens in the treatment of breast cancer. Cancer Treat. Rev. 1976, 3, 205-216.
205. Legha, S. S.; Slavik, M.; Carter, S. K. Nafoxidine-an antiestrogen for the treatment of breast cancer. Cancer 1976, 38, 1535-1541.
206. Jordan, V. C.; Collins, M. M.; Rowsby, L.; Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 1977, 75, 305-316.
207. Borgna, J. L.; Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 1981, 256, 859-868.
208. Coezy, E.; Borgna, J. L.; Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982, 42, 317-323.
209. Black, L. J.; Jones, C. D.; Falcone, J. F. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci. 1983, 32, 1031-1036.
210. Clemens, J. A.; Bennett, D. R.; Black, L. J.; Jones, C. D. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 1983, 32, 2869-2875.
211. Scholl, S. M.; Huff, K. K.; Lippman, M. E. Antiestrogenic effects of LY 117018 in MCF-7 cells. Endocrinology 1983, 113, 611-617.
212. Jordan, V. C.; Gosden, B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 1983, 113, 463-468.
213. Allen, K. E.; Clark, E. R.; Jordan, V. C. Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure - activity relationships. Br. J. Pharmacol. 1980, 71, 83-91.
214. Buzdar, A. U.; Marcus, C.; Holmes, F.; Hug, V.; Hortobagyi, G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988, 45, 344-345.
215. Gradishar, W.; Glusman, J.; Lu, Y.; Vogel, C.; Cohen, F. J.; Sledge, G. W., Jr. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000, 88, 2047-2053.
216. Jordan, V. C. Tamoxifen: the herald of a new era of preventive therapeutics [editorial; comment]. J. Natl. Cancer Inst. 1997, 89, 747-749.
217. Jordan, V. C. Designer estrogens. Sci. Am. 1998, 279, 60-67.
218. Jordan, V. C. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 2001, 61, 5683-5687.
219. Persson, I.; Weiderpass, E.; Bergkvist, L.; Bergstrom, R.; Schairer, C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer, Causes Control, Pap. Symp. 1999, 10, 253-260.
220. Colditz, G. A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 1998, 90, 814-823.
221. Schairer, C.; Lubin, J.; Troisi, R.; Sturgeon, S.; Brinton, L.; Hoover, R. Menopausal estrogen and estrogen - progestin replacement therapy and breast cancer risk [see comments]. JAMA, J. Am. Med. Assoc. 2000, 283, 485-491.
222. Terenius, L. Structure - activity relationships of anti-oestrogens with regard to interaction with 17-beta-oestradiol in the mouse uterus and vagina. Acta Endocrinol. 1971, 66, 431-447.
223. Jordan, V. C.; Dix, C. J.; Rowsby, L.; Prestwich, G. Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat. Mol. Cell. Endocrinol. 1977, 7, 177-192.
224. Jordan, V. C.; Prestwich, G. Effect of non-steroidal anti-oestrogens on the concentration of rat uterine progesterone receptors. J. Endocrinol. 1978, 76, 363-364.
225. Jordan, V. C.; Rowsby, L.; Dix, C. J.; Prestwich, G. Dose-related effects of non-steroidal antioestrogens and oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J. Endocrinol. 1978, 78, 71-81.
226. Fromson, J. M.; Pearson, S.; Bramah, S. The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica 1973, 3, 693-709.
227. Lyman, S. D.; Jordan, V. C. Metabolism of nonsteroidal antiestrogens. Estrogen/Antiestrogen Action and Breast Cancer Therapy; University of Wisconsin Press: Madison, WI, 1986; pp 191-219.
228. Robinson, S. P.; Langan-Fahey, S. M.; Jordan, V. C. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 1989, 25, 1769-1776.
229. Levenson, A. S.; Jordan, V. C. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 1997, 57, 3071- 3078.
230. Osborne, C. K.; Hobbs, K.; Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985, 45, 584-590.
231. Jordan, V. C.; Robinson, S. P. Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc. 1987, 46, 1870- 1874.
232. Jordan, V. C.; Lababidi, M. K.; Mirecki, D. M. Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur. J. Cancer 1990, 26, 718-721.
233. Jordan, V. C.; Lababidi, M. K.; Langan-Fahey, S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl. Cancer Inst. 1991, 83, 492-496.
234. Jordan, V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer 1976, 12, 419-424.
235. Jordan, V. C.; Allen, K. E. Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer 1980, 16, 239-251.
236. Anzano, M. A.; Peer, C. W.; Smith, J. M.; Mullen, L. T.; Shrader, M. W.; Logsdon, D. L.; Driver, C. L.; Brown, C. C.; Roberts, A. B.; Sporn, M. B. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 1996, 88, 123-125.
237. Black, L. J.; Sato, M.; Rowley, E. R.; Magee, D. E.; Bekele, A.; Williams, D. C.; Cullinan, G. J.; Bendele, R.; Kauffman, R. F.; Bensch, W. R.; et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 1994, 93, 63-69.
238. Sato, M.; McClintock, C.; Kim, J.; Turner, C. H.; Bryant, H. U.; Magee, D.; Slemenda, C. W. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 1994, 9, 715-724.
239. Sato, M.; Rippy, M. K.; Bryant, H. U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996, 10, 905-912.
240. Turner, C. H.; Sato, M.; Bryant, H. U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994, 135, 2001-2005.
241. Wright, C. D.; Garrahan, N. J.; Stanton, M.; Gazet, J. C.; Mansell, R. E.; Compston, J. E. Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. J. Bone Miner. Res. 1994, 9, 153-159.
242. Kenny, A. M.; Prestwood, K. M.; Pilbeam, C. C.; Raisz, L. G. The short-term effects of tamoxifen on bone turnover in older women. J. Clin. Endocrinol. Metab. 1995, 80, 3287-3291.
243. Love, R. R.; Barden, H. S.; Mazess, R. B.; Epstein, S.; Chappell, R. J. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch. Intern. Med. 1994, 154, 2585-2588.
244. Powles, T. J.; Hickish, T.; Kanis, J. A.; Tidy, A.; Ashley, S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 1996, 14, 78-84.
245. Kristensen, B.; Ejlertsen, B.; Dalgaard, P.; Larsen, L.; Holmegaard, S. N.; Transbol, I.; Mouridsen, H. T. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol. 1994, 12, 992-997.
246. Heaney, R. P.; Draper, M. W. Raloxifene and estrogen: comparative bone-remodeling kinetics. J. Clin. Endocrinol. Metab. 1997, 82, 3425-3429.
247. Delmas, P. D.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux, A. C.; Shah, A. S.; Huster, W. J.; Draper, M.; Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [see comments]. N. Engl. J. Med. 1997, 337, 1641-1647.
248. Ettinger, B.; Black, D. M.; Mitlak, B. H.; Knickerbocker, R. K.; Nickelsen, T.; Genant, H. K.; Christiansen, C.; Delmas, P. D.; Zanchetta, J. R.; Stakkestad, J.; Gluer, C. C.; Krueger, K.; Cohen, F. J.; Eckert, S.; Ensrud, K. E.; Avioli, L. V.; Lips, P.; Cummings, S. R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators [see comments]. JAMA, J. Am. Med. Assoc. 1999, 282, 637-645.
249. Cummings, S. R.; Eckert, S.; Krueger, K. A.; Grady, D.; Powles, T. J.; Cauley, J. A.; Norton, L.; Nickelsen, T.; Bjarnason, N. H.; Morrow, M.; Lippman, M. E.; Black, D.; Glusman, J. E.; Costa, A.; Jordan, V. C. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA, J. Am. Med. Assoc. 1999, 281, 2189-2197.
250. Cauley, J. A.; Norton, L.; Lippman, M. E.; Eckert, S.; Krueger, K. A.; Purdie, D. W.; Farrerons, J.; Karasik, A.; Mellstrom, D.; Ng, K. W.; Stephan, J. J.; Powles, T. J.; Morrow, M.; Costa, A.; Silfen, S. L.; Walls, E. L.; Schmitt, H.; Muchmore, D. B.; Jordan, V. C. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. 2001, 65 (2), 125-134.
251. Satyaswaroop, P. G.; Zaino, R. J.; Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 1984, 44, 4006-4010.
252. Gottardis, M. M.; Robinson, S. P.; Satyaswaroop, P. G.; Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988, 48, 812-815.
253. Horwitz, R. I.; Feinstein, A. R.; Horwitz, S. M.; Robboy, S. J. Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies. Lancet 1981, 2, 66-68.
254. Assikis, V. J.; Neven, P.; Jordan, V. C.; Vergote, I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer 1996, 32A, 1464-1476.
255. Clark, A. J. The reaction between acetyl choline and muscle cells. J. Physiol. 1926, 61, 530-546.
256. Gaddum, J. H. The action of adrenalin and ergotamine on the uterus of the rabbit. J. Physiol. 1926, 61, 141-150.
257. Stephenson, R. P. A modification of receptor theory. Br. J. Pharmacol. 1956, 11, 379-392.
258. Ariens, E. J.; Simonis, A. M. A molecular basis for drug action. J. Pharm. Pharmacol. 1964, 16, 137-157.
259. Clark, J. H.; Peck, E. J. Nuclear retention of receptor - oestrogen complex and nuclear acceptor sites. Nature 1976, 260, 635-637.
260. Jordan, V. C.; Naylor, K. E. The binding of [3H]-oestradiol-17 beta in the immature rat uterus during the sequential administration of non-steroidal anti-oestrogens. Br. J. Pharmacol. 1979, 65, 167-173.
261. Engel, L. W.; Young, N. A. Human breast carcinoma cells in continuous culture: a review. Cancer Res. 1978, 38, 4327-4339.
262. Soule, H. D.; Vazguez, J.; Long, A.; Albert, S.; Brennan, M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 1973, 51, 1409-1416.
263. Brooks, S. C.; Locke, E. R.; Soule, H. D. Estrogen receptor in a human cell line (MCF-7) from breast cancercinoma. J. Biol. Chem. 1973, 248, 6251-6253.
264. Engel, I. W.; Young, N. A.; Tralka, T. S.; Lippman, M. E.; O'Brien, S. J.; Joyce, M. J. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res. 1978, 38, 3352-3364.
265. Keydar, I.; Chen, L.; Karby, S.; Weiss, F. R.; Delarea, J.; Radu, M.; Chaitcik, S.; Brenner, H. J. Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J. Cancer 1979, 15, 659-670.
266. Lippman, M. E.; Bolan, G. Oestrogen-responsive human breast cancer in long-term tissue culture. Nature 1975, 256, 592-593.
267. Lippman, M. E.; Bolan, G.; Huff, K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976, 36, 4595-4601.
268. Shafie, S. M. Estrogen and the growth of breast cancer: new evidence suggests indirect action. Science 1980, 209, 701-702.
269. Berthois, Y.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 2496-2500.
270. Bindal, R. D.; Carlson, K. E.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. J. Steroid Biochem. 1988, 31, 287-293.
271. Lieberman, M. E.; Maurer, R. A.; Gorski, J. Estrogen control of prolactin synthesis in vitro. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 5946-5949.
272. Welshons, W. V.; Wolf, M. F.; Murphy, C. S.; Jordan, V. C. Estrogenic activity of phenol red. Mol. Cell. Endocrinol. 1988, 57, 169-178.
273. Jordan, V. C. The control of hormone-dependent breast cancer growth-are we talking about estrogen alone? Eur. J. Cancer Clin. Oncol. 1988, 24, 1245-1248.
274. Lieberman, M. E.; Gorski, J.; Jordan, V. C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J. Biol. Chem. 1983, 258, 4741-4745.
275. Lieberman, M. E.; Jordan, V. C.; Fritsch, M.; Santos, M. A.; Gorski, J. Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J. Biol. Chem. 1983, 258, 4734-4740.
276. Jordan, V. C.; Lieberman, M. E.; Cormier, E.; Koch, R.; Bagley, J. R.; Ruenitz, P. C. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Mol. Pharmacol. 1984, 26, 272-278.
277. Jordan, V. C.; Koch, R.; Mittal, S.; Schneider, M. R. Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro. Br. J. Pharmacol. 1986, 87, 217-223.
278. Jordan, V. C.; Koch, R.; Langan, S.; McCague, R. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. Endocrinology 1988, 122, 1449-1454.
279. Jordan, V. C.; Koch, R. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone. Endocrinology 1989, 124, 1717-1726.
280. Belleau, B. A molecular theory of drug action based on induced conformational pertubations of receptors. J. Med. Chem. 1964, 7, 776-784.
281. Robertson, D. W.; Katzenellenbogen, J. A.; Hayes, J. R.; Katzenellenbogen, B. S. Antiestrogen basicity - activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity. J. Med. Chem. 1982, 25, 167-171.
282. Tate, A. C.; Greene, G. L.; DeSombre, E. R.; Jensen, E. V.; Jordan, V. C. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res. 1984, 44, 1012-1018.
283. Murphy, C. S.; Langan-Fahey, S. M.; McCague, R.; Jordan, V. C. Structure - function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol. Pharmacol. 1990, 38, 737-743.
284. Murphy, C. S.; Jordan, V. C. Structural components necessary for the antiestrogenic activity of tamoxifen. J. Steroid Biochem. 1989, 34, 407-411.
285. Murphy, C. S.; Parker, C. J.; McCague, R.; Jordan, V. C. Structure - activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol. Pharmacol. 1991, 39, 421-428.
286. Greene, G.; Fitch, F. W.; Jensen, E. V. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 157-161.
287. Furr, B. J.; Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 1984, 25, 127-205.
288. Norris, J. D.; Fan, D.; Wagner; McDonnell, D. P. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol. Endocrinol. 1996, 10, 1605-1616.
289. Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10, 119-131.
290. Levenson, A. S.; Catherino, W. H.; Jordan, V. C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol. 1997, 60, 261-268.
291. Levenson, A. S.; Tonetti, D. A.; Jordan, V. C. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br. J. Cancer 1998, 77, 1812-1819.
292. Levenson, A. S.; Svoboda, K. M.; Kwaan, H. C.; Jordan, V. C. Agonist activity of antiestrogen - receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Lett. 1998, 125, 215-220.
293. Wolf, D. M.; Jordan, V. C. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat. 1994, 31, 117-127.
294. Wolf, D. M.; Jordan, V. C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 1994, 31, 129-138.
295. Katzenellenbogen, B. S.; Montano, M. M.; Le Goff, P.; Schodin, D. J.; Kraus, W. L.; Bhardwaj, B.; Fujimoto, N. Antiestrogens: mechanisms and actions in target cells. J. Steroid Biochem. Mol. Biol. 1995, 53, 387-393.
296. Jordan, V. C. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J. Natl. Cancer Inst. 1998, 90, 967-971.
297. Jiang, S. Y.; Jordan, V. C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor [see comments]. J. Natl. Cancer Inst. 1992, 84, 580-591.
298. Catherino, W. H.; Wolf, D. M.; Jordan, V. C. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol. Endocrinol. 1995, 9, 1053-1063.
299. Jeng, M. H.; Jiang, S. Y.; Jordan, V. C. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett. 1994, 82, 123-128.
300. Anghel, S. I.; Perly, V.; Melancon, G.; Barsalou, A.; Chagnon, S.; Rosenauer, A.; Miller, W. H., Jr.; Mader, S. Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens. J. Biol. Chem. 2000, 275, 20867-20872.
301. Webb, P.; Nguyen, P.; Valentine, C.; Weatherman, R. V.; Scanlan, T. S.; Kushner, P. J. An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen. J. Biol. Chem. 2000, 275, 37552-37558.
302. Levenson, A. S.; Jordan, V. C. Selective Oestrogen Receptor Modulation: Molecular Pharmacology for the Millennium. Eur. J. Cancer 1999, 35, 1628-1639.
303. Levenson, A. S.; Jordan, V. C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 1998, 58, 1872-1875.
304. Liu, H.; Lee, E. S.; De Los Reyes, A.; Zapf, J. W.; Jordan, V. C. Silencing and reactivation of the selective estrogen receptor modulator - estrogen receptor alpha complex. Cancer Res. 2001, 61, 3632-3639.
305. Bentrem, D.; Dardes, R.; Liu, H.; MacGregor-Schafer, J.; Zapf, J.; Jordan, V. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 2001, 142, 838-846.
306. Liu, H.; Park, W.; Bentrem, D.; McKian, K. P.; De Los Reyes, A.; MacGregor Schafer, J.; Zapf, J.; Jordan, V. C. Structure - function relationships of the raloxifene - estrogen receptor alpha complex for regulating transforming growth factor alpha expression in breast cancer cells. J. Biol. Chem. 2002, 277, 9189-9198.
307. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14105-14110.
308. Yamamoto, Y.; Wada, O.; Suzawa, M.; Yogiashi, Y.; Yano, T.; Kato, S.; Yanagisawa, J. The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. J. Biol. Chem. 2001, 276, 42684-42691.
309. Norris, J. D.; Fan, D.; Sherk, A.; McDonnell, D. P. A negative coregulator for the human ER. Mol. Endocrinol. 2002, 16, 449-468.
310. Shang, Y.; Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295, 2465-2468.
311. Norris, J. D.; Fan, D.; Kerner, S. A.; McDonnell, D. P. Identification of a third autonomous activation domain within the human estrogen receptor. Mol. Endocrinol. 1997, 11, 747-754.
312. Pink, J. J.; Jordan, V. C. Models ofestrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996, 56, 2321-2330.
313. MacGregor Schafer, J. I.; Liu, H.; Tonetti, D. A.; Jordan, V. C. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res. 1999, 59, 4308-4313.
314. Zhigang, L.; Joyal, J. L.; Sacks, D. B. Calmodulin enhances the stability of the estrogen receptor. J. Biol. Chem. 2001, 276, 17354-17360.
315. Dauvois, S.; White, R.; Parker, M. G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106, 1377-1388.
316. Dauvois, S.; Danielian, P. S.; White, R.; Parker, M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4037-4041.
317. Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A.; Li, Y.; Gustafsson, J.; Carlquist, M. Structural insights into the mode of action of a pure antiestrogen. Structure 2001, 9 (February), 145-153.
318. Devin-Leclerc, J.; Meng, X.; Delahaye, F.; Leclerc, P.; Baulieu, E.; Catelli, M. Interaction and dissociation by ligands of estrogen receptor and hsp90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol. Endocrinol. 1998, 12, 842-854.
319. Wijayaratne, A. L.; McDonnell, D. P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276, 35684- 35692.
320. Sutherland, R. L.; Murphy, L. C.; San Foo, M.; Green, M. D.; Whybourne, A. M.; Krozowski, Z. S. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 1980, 288, 273-275.
321. Faye, J. C.; Lasserre, B.; Bayard, F. Antiestrogen specific, high affinity saturable binding sites in rat uterine cytosol. Biochem. Biophys. Res. Commun. 1980, 93, 1225-1231.
322. Sudo, K.; Monsma, F. J., Jr.; Katzenellenbogen, B. S. Antiestrogen-binding sites distinct from the estrogen receptor: subecellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology 1983, 112, 425-434.
323. Poirot, M.; Chailleux, C.; Fargin, A.; Bayard, F.; Faye, J. C. A potent and selective photoaffinity probe for the anti-estrogen binding site of rat liver. J. Biol. Chem. 1990, 265, 17039-17043.
324. Brandes, L. J.; Hermonat, M. W. A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes. Biochem. Biophys. Res. Commun. 1984, 123, 724-728.
325. Brandes, L. J.; Macdonald, L. M.; Bogdanovic, R. P. Evidence that the antiestrogen binding site is a histamine or histamine-like receptor. Biochem. Biophys. Res. Commun. 1985, 126, 905- 910.
326. Brandes, L. J.; LaBella, F. S.; Warrington, R. C. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J. Natl. Cancer Inst. 1991, 83, 1329-1336.
327. Jones, J. A.; Albright, K. D.; Christen, R. D.; Howell, S. B.; McClay, E. F. Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Res. 1997, 57, 2657-2660.
328. Brandes, L. J.; Bracken, S. P.; Ramsey, E. W. N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J. Clin. Oncol. 1995, 13, 1398-1403.
329. Brandes, L. J.; Bracken, S. P. The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethamine-HCL, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study. Breast Cancer Res. Treat. 1998, 49, 61-68.
330. Mesange, F.; Sebbar, M.; Kedjouar, B.; Capdevielle, J.; Guillemot, J. C.; Ferrara, P.; Bayard, F.; Delarue, F.; Faye, J. C.; Poirot, M. Microsomal epoxide hydrolase of rat liver is a subunit of the anti-oestrogen-binding site. Biochem. J. 1998, 334, 107-112.
331. Fritz, P.; Murdter, T. E.; Eichelbaum, M.; Siegle, I.; Weissert, M.; Zanger, U. M. Microsomal epoxide hydrolase expression as a predictor of tamoxifen response in primary breast cancer: a retrospective exploratory study with long-term follow-up. J. Clin. Oncol. 2001, 19, 3-9.
332. Ruenitz, P. C.; Bagley, J. R. Metabolism of nitromiphene (CI 628) in the immature female rat: role of gastrointestinal microflora in the biotransformation of a triarylethylene antiestrogen. Cancer Res. 1986, 46, 6255-6259.
333. Hwang, P. L. High-affinity binding sites for oxygenated sterols in rat liver microsomes: possible identity with antiestrogen binding sites. Biochim. Biophys. Acta 1990, 1033, 154-161.
334. Delarue, F.; Kedjouar, B.; Mesange, F.; Bayard, F.; Faye, J. C.; Poirot, M. Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity. Biochem. Pharmacol. 1999, 57, 657-661.
335. Boss, S. M.; Huster, W. J.; Neild, J. A.; Glant, M. D.; Eisenhut, C. C.; Draper, M. W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 1997, 177, 1458-1464.
336. Walsh, B. W.; Kuller, L. H.; Wild, R. A.; Paul, S.; Farmer, M.; Lawrence, J. B.; Shah, A. S.; Anderson, P. W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, J. Am. Med. Assoc. 1998, 279, 1445-1451.
337. Love, R. R.; Wiebe, D. A.; Feyzi, J. M.; Newcomb, P. A.; Chappell, R. J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 1994, 86, 1534-1539.
338. Howell, A.; DeFriend, D.; Robertson, J.; Blamey, R.; Walton, P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer [see comments]. Lancet 1995, 345, 29-30.
339. O'Regan, R. M.; Gajdos, C.; Dardes, R. C.; De Los Reyes, A.; Park, W.; Rademaker, A. W.; Jordan, V. C. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J. Natl. Cancer Inst. 2002, 94, 274-283.
340. Horlein, A. J.; Naar, A. M.; Heinzel, T.; Torchia, J.; Gloss, B.; Kurokawa, R.; Ryan, A.; Kamei, Y.; Soderstrom, M.; Glass, C. K.; et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995, 377, 397-404.
341. Chen, J. D.; Umesono, K.; Evans, R. M. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7567-7571.
342. Kurokawa, R.; Soderstrom, M.; Horlein, A.; Halachmi, S.; Brown, M.; Rosenfeld, M. G.; Glass, C. K. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995, 377, 451-454.
343. Zamir, I.; Dawson, J.; Lavinsky, R. M.; Glass, C. K.; Rosenfeld, M. G.; Lazar, M. A. Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14400-14405.
344. Jackson, T. A.; Richer, J. K.; Bain, D. L.; Takimoto, G. S.; Tung, L.; Horwitz, K. B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 1997, 11, 693-705.
345. Montano, M. M.; Ekena, K.; Delage-Mourroux, R.; Chang, W.; Martini, P.; Katzenellenbogen, B. S. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6947-6952.
346. Dana, S. L.; Hoener, P. A.; Wheeler, D. A.; Lawrence, C. B.; McDonnell, D. P. Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. Mol. Endocrinol. 1994, 8, 1193-1207.
347. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene [see comments] [published erratum appears in Science 1997 275 (5304, February 28), 1249]. Science 1996, 273, 1222-1225.
348. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Correction: raloxifene response needs more than an element [letter]. Science 1997, 275, 1249.
349. Gallagher, A.; Chambers, T. J.; Tobias, J. H. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 1993, 133, 2787-2791.
350. Speirs, V.; Parkes, A. T.; Kerin, M. J.; Walton, D. S.; Carleton, P. J.; Fox, J. N.; Atkin, S. L. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res. 1999, 59, 525-528.
351. Dotzlaw, H.; Leygue, E.; Watson, P. H.; Murphy, L. C. Estrogen receptor-beta messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res. 1999, 59, 529-532.
352. Speirs, V.; Malone, C.; Walton, D. S.; Kerin, M. J.; Atkin, S. L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999, 59, 5421-5424.
353. Rosenfeld, C. S.; Ganjam, V. K.; Taylor, J. A.; Yuan, X.; Stiehr, J. R.; Hardy, M. P.; Lubahn, D. B. Transcription and translation of estrogen receptor-beta in the male reproductive tract of estrogen receptor-alpha knock-out and wild-type mice. Endocrinology 1998, 139, 2982-2987.
354. Rosenfeld, C. S.; Yuan, X.; Manikkam, M.; Calder, M. D.; Garverick, H. A.; Lubahn, D. B. Cloning, sequencing and localization of bovine estrogen receptor-beta within the ovarian follicle. Biol. Reprod. 1999, 60, 691-697.
355. Fuqua, S. A.; Schiff, R.; Parra, I.; Friedrichs, W. E.; Su, J. L.; McKee, D. D.; Slentz-Kesler, K.; Moore, L. B.; Willson, T. M.; Moore, J. T. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res. 1999, 59, 5425-5428.
356. Witte, D.; Chirala, M.; Younes, A.; Li, Y.; Younes, M. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum. Pathol. 2001, 32, 940-944.
357. McInerney, E. M.; Weis, K. E.; Sun, J.; Mosselman, S.; Katzenellenbogen, B. S. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras. Endocrinology 1998, 139, 4513-4522. JM020449Y